Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Price:
549.95
INR
-0.29%
Market Closed
Market Cap:
11B
INR
Balance Sheet
Balance Sheet Decomposition
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd
| Current Assets | 5.2B |
| Cash & Short-Term Investments | 2B |
| Receivables | 2.2B |
| Other Current Assets | 980.9m |
| Non-Current Assets | 2.6B |
| Long-Term Investments | 5.2m |
| PP&E | 1.8B |
| Intangibles | 3.2m |
| Other Non-Current Assets | 724.4m |
Balance Sheet
Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Ltd
Currency: INR
Millions
Annual
| Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
115
|
125
|
117
|
146
|
55
|
122
|
114
|
183
|
225
|
138
|
|
| Cash |
40
|
33
|
31
|
66
|
55
|
122
|
114
|
183
|
225
|
57
|
|
| Cash Equivalents |
75
|
92
|
86
|
80
|
0
|
0
|
0
|
0
|
0
|
81
|
|
| Short-Term Investments |
0
|
11
|
103
|
110
|
181
|
342
|
808
|
970
|
914
|
1 389
|
|
| Total Receivables |
1 441
|
798
|
917
|
1 095
|
1 456
|
1 335
|
1 464
|
1 513
|
1 708
|
2 160
|
|
| Accounts Receivables |
1 190
|
798
|
907
|
1 094
|
1 225
|
1 013
|
1 113
|
1 159
|
1 365
|
1 618
|
|
| Other Receivables |
251
|
0
|
10
|
0
|
232
|
322
|
351
|
354
|
344
|
541
|
|
| Inventory |
218
|
275
|
373
|
454
|
362
|
474
|
466
|
727
|
700
|
772
|
|
| Other Current Assets |
0
|
268
|
301
|
379
|
187
|
206
|
212
|
135
|
125
|
11
|
|
| Total Current Assets |
1 774
|
1 477
|
1 811
|
2 183
|
2 240
|
2 480
|
3 065
|
3 529
|
3 672
|
4 467
|
|
| PP&E Net |
629
|
913
|
997
|
1 073
|
1 134
|
1 132
|
1 119
|
1 476
|
1 569
|
1 825
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
1 134
|
1 132
|
1 119
|
1 476
|
1 569
|
1 825
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
169
|
235
|
308
|
384
|
460
|
563
|
|
| Intangible Assets |
53
|
3
|
4
|
3
|
4
|
4
|
4
|
4
|
3
|
3
|
|
| Goodwill |
0
|
92
|
92
|
92
|
92
|
92
|
92
|
0
|
0
|
0
|
|
| Note Receivable |
125
|
252
|
88
|
91
|
160
|
152
|
258
|
277
|
601
|
661
|
|
| Long-Term Investments |
0
|
1
|
1
|
1
|
2
|
2
|
7
|
19
|
5
|
1
|
|
| Other Long-Term Assets |
0
|
20
|
61
|
29
|
28
|
32
|
49
|
40
|
24
|
46
|
|
| Other Assets |
0
|
92
|
92
|
92
|
92
|
92
|
92
|
0
|
0
|
0
|
|
| Total Assets |
2 580
N/A
|
2 757
+7%
|
3 053
+11%
|
3 472
+14%
|
3 660
+5%
|
3 894
+6%
|
4 594
+18%
|
5 344
+16%
|
5 874
+10%
|
7 003
+19%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
453
|
398
|
325
|
435
|
440
|
512
|
568
|
717
|
512
|
724
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
42
|
16
|
47
|
59
|
61
|
69
|
|
| Short-Term Debt |
507
|
524
|
450
|
486
|
301
|
38
|
0
|
20
|
20
|
11
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
63
|
58
|
18
|
4
|
4
|
0
|
0
|
0
|
|
| Other Current Liabilities |
147
|
126
|
71
|
71
|
52
|
85
|
117
|
109
|
130
|
118
|
|
| Total Current Liabilities |
1 107
|
1 048
|
909
|
1 049
|
853
|
656
|
736
|
905
|
723
|
923
|
|
| Long-Term Debt |
255
|
194
|
124
|
69
|
17
|
9
|
1
|
0
|
0
|
0
|
|
| Deferred Income Tax |
46
|
45
|
59
|
72
|
56
|
54
|
57
|
65
|
79
|
115
|
|
| Minority Interest |
29
|
3
|
3
|
3
|
4
|
4
|
4
|
0
|
0
|
0
|
|
| Other Liabilities |
30
|
32
|
35
|
36
|
37
|
41
|
43
|
45
|
47
|
37
|
|
| Total Liabilities |
1 467
N/A
|
1 322
-10%
|
1 130
-15%
|
1 230
+9%
|
966
-21%
|
763
-21%
|
841
+10%
|
1 015
+21%
|
849
-16%
|
1 075
+26%
|
|
| Equity | |||||||||||
| Common Stock |
163
|
163
|
200
|
200
|
200
|
200
|
200
|
200
|
200
|
200
|
|
| Retained Earnings |
950
|
1 273
|
1 724
|
2 042
|
1 846
|
2 288
|
2 910
|
3 484
|
4 183
|
5 086
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
646
|
646
|
646
|
646
|
646
|
646
|
|
| Other Equity |
0
|
0
|
0
|
0
|
1
|
3
|
3
|
2
|
5
|
4
|
|
| Total Equity |
1 113
N/A
|
1 436
+29%
|
1 924
+34%
|
2 242
+17%
|
2 693
+20%
|
3 131
+16%
|
3 753
+20%
|
4 329
+15%
|
5 025
+16%
|
5 928
+18%
|
|
| Total Liabilities & Equity |
2 580
N/A
|
2 757
+7%
|
3 053
+11%
|
3 472
+14%
|
3 660
+5%
|
3 894
+6%
|
4 594
+18%
|
5 344
+16%
|
5 874
+10%
|
7 003
+19%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
16
|
16
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
20
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
